Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lalikinogene sifuplasmid
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Lalikinogene sifuplasmid is a recombinant DNA plasmid (pGX6010) that encodes human interleukin-12 (IL-12) subunits alpha (IL12A) and beta (IL12B). Developed by Inovio Pharmaceuticals, it is one of the two active plasmid components of Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), which received FDA accelerated approval on October 30, 2026. Voceryq is indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP), a rare chronic disease of the airways caused by human papillomavirus (HPV) types 6 and 11. Within the combination, lalikinogene sifuplasmid acts as an immunotherapy adjuvant, expressing IL-12 to enhance host cell-mediated immune responses against HPV-infected cells, while the co-administered plasmid (doruxapapogene ralaplasmid) encodes the HPV-6 and HPV-11 E6 and E7 antigens. The therapy is administered via intramuscular injection followed by electroporation using the CELLECTRA 5PSP device.
- Other names
- lalikinogene sifuplasmid-gxfd
02
Targets
Beyond the preview
Go deeper on lalikinogene sifuplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lalikinogene sifuplasmid.